Schedule and Registration
Interested participants should choose one of the following sets of dates to attend this two-day virtual workshop:
- March 7-8
- April 3-4
- May 4-5
Each workshop is scheduled for 9 a.m. to 5 p.m. on both days.
Registration for this workshop is now closed. Please check our course catalog for similar opportunities in the future.
The Racial Equity Institute’s two-day Phase 1 training is designed to develop the capacity of participants to better understand racism in its institutional and structural forms. Moving away from a focus on personal bigotry and bias, this workshop presents a historical, cultural and structural analysis of racism. With shared language and a clearer understanding of how institutions and systems are producing unjust and inequitable outcomes, participants should leave the training better equipped to begin to work for change.
Who Should Attend
This training is open to local health department staff in North Carolina.
Participants in this training should be willing and able to dedicate two full days (9 a.m.-5 p.m.) of active engagement for a virtual workshop. Specifically, participants will need to:
- Have working camera and audio.
- Commit to being on camera and audio at all times during the training.
- Attend both days.
Additionally, participants should:
- Be involved in equity work already.
- Preferably have completed an REI Groundwater session prior to the Phase I workshop (recommended but not required).
For more information about the sessions, contact Cherelle Whitfield.
Cosponsors and Participant Fee
These sessions are supported through a contract to the North Carolina Institute for Public Health from the North Carolina Division of Public Health as part of the American Rescue Plan Act (ARPA) Public Health Workforce Development Initiative investment in North Carolina’s public health workforce. Participants will not be charged a registration fee. Due to limited space in these trainings, registration should be a firm commitment to attend.
September 21, 2023 New research conducted by the UNC Gillings School of Global Public Health and the Cleveland Clinic shows that ritonavir-boosted nirmatrelvir (Paxlovid) and molnupiravir (Lagevrio) substantially reduced COVID-19 hospitalization and death among high-risk patients, even against the most recent Omicron subvariants BQ.1.1 and XBB.1.5.